Danzhu Fuyuan Granule

PreclinicalSmall molecule

Danzhu Fuyuan Granule is one of 37 small molecule programs targeting Membranous Nephropathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Membranous NephropathyActive, not recruiting

Membranous NephropathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

75 competitors in Membranous Nephropathy

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

16 2

Neoral

Novartis

Phase 3

4 3

Gazyva

Roche

Phase 3

3 4

Medrol

Pfizer

Phase 3

2 5

Prograf

VVeloxis Pharmaceuticals

Phase 3

6 6

Brukinsa

BBeOne Medicines

Phase 3

1 7

Felzartamab

Biogen

Phase 3

1 8

Tylenol

Benadryl

Povetacicept

Vertex Pharmaceuticals

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Membranous Nephropathy1 trial

The Effect of Danzhu Fuyuan Granule as Adjunctive Therapy for Chronic Stable Angina, Vascular Dementia and Idiopathic Membranous Nephropathy: A Bayesian Basket Trial

Unknown status·JJingqing Hu·N/A·NCT04498962·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Danzhu Fuyuan Granule. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Danzhu Fuyuan Granule compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Danzhu Fuyuan Granule. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jingqing Hu company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: JJingqing Hu

Danzhu Fuyuan Granule

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Membranous Nephropathy1 trial

References

Drug Info

Quick Facts

Related News